Richard H. Nagelberg, DDS, director of medical affairs at OraPharma, addresses the growing use of compounded alternatives to FDA-approved dental therapies and the critical safety, legal, and ethical considerations every dental practice must understand.
Q:What role does compounding play in dentistry?
A: Compounding serves legitimate purposes when commercial medications cannot meet specific patient needs. Appropriate dental applications include customized mouthwashes for oral ulcerations, topical anesthetics for patients with sensitivities, anxiety medications in palatable forms like lollipops, and specialized formulations for conditions like burning mouth syndrome or severe dry mouth. The majority of compounded formulations used by dentists are for direct application to the oral cavity, usually as mouthwashes or oral pastes. These represent compounding’s rightful place and address genuine therapeutic gaps where no commercial alternative exists.
Q: When does compounding become problematic in dental practice?
A: Problems arise when compounded pharmaceuticals are used as direct substitutes for FDA-approved medications without clear medical justification. The Federal Food, Drug and Cosmetic Act Section 503A explicitly prohibits compounding drugs that are essentially copies of commercially available products unless there is documented medical necessity. It is illegal to compound a copy of a commercially available product when there are no documented medical reasons or patient-specific needs that would justify an alternative formulation.
Q: What specific concerns exist with compounded minocycline gels?
A: Compounded minocycline gels are being marketed as alternatives to Arestin (OraPharma), the FDA-approved locally delivered antibiotic for periodontal therapy. The differences create significant concerns: First, these gels lack FDA approval and have not undergone rigorous clinical trials or safety evaluations. Second, Arestin uses microsphere technology providing sustained minocycline activity for at least 14 days, while compounded gels typically remain active for only a few days, potentially compromising treatment outcomes. Third, minocycline is unstable when exposed to light, heat, and moisture. Without proven stability testing, compounded formulations may degrade unpredictably, reducing effectiveness and increasing contamination risk.
Q: Are there historical precedents showing the risks of inappropriate compounding?
A: Unfortunately, yes. Research has documented 2 patient deaths in dental settings attributed to compounded topical anesthetics containing tetracaine, epinephrine, and lidocaine used without proper oversight. The 2012 fungal meningitis outbreak linked to contaminated compounded steroid injections caused over 100 deaths. These cases highlight that when compounded products fail or cause harm, responsibility often falls directly on the prescribing practitioner.
Q: What are the liability risks for dental practices using compounded alternatives?
A: Multiple liability exposures exist. Malpractice insurance may exclude coverage for adverse events related to non-FDA approved compounded drugs, especially when FDA-approved alternatives were available. If a patient is harmed and the dentist failed to disclose the substitution, coverage could be denied, leaving the provider personally liable. Additionally, selecting an unproven, short-acting compounded gel over a well-studied, sustained-release FDA-approved therapy could be viewed as falling below the standard of care.
Q: What informed consent obligations exist when using compounded drugs?
A: Dentists must inform patients when a compounded product is used instead of an FDA-approved option. Patients should know the product has not been tested for safety or efficacy and may carry unknown risks. A clear disclosure might be: “This medication is compounded, which means it has not been FDA-approved or studied the way commercial drugs are. We’re using it because…”
Q: What risk management strategies should dental practices implement?
A: Practices should review all compounded products currently in use and identify any FDA-approved alternatives. Document any legitimate medical reasons for using compounded versions. Implement standardized informed consent protocols so patients understand regulatory status, risks, and alternatives. Confirm with malpractice carriers how compounded drug use affects coverage.
Q: How significant are the health consequences of undertreating periodontitis?
A: The stakes are substantial. Inadequately treated periodontitis can lead to tooth loss, bone destruction, increased risks of cardiovascular disease, and diabetes complications. Using short-acting, unproven alternatives in place of proven sustained-release therapies increases the risk of poor outcomes. Importantly, “lack of effect” is itself an adverse event and disease progression may continue unnoticed until irreversible damage occurs.
Q: What’s the bottom line for dental practices?
A: Compounding has its place in dentistry for patients with genuine unmet needs. However, substituting compounded products for FDA-approved therapies without clear medical justification endangers patients, exposes dentists to liability, and undermines professional standards. Clinical decisions must be driven by evidence and patient need, not economics alone. When well-studied, FDA-approved therapies like Arestin exist, they remain the standard for evidence-based, ethical dental care.
Dr. Nagelberg is director of medical affairs at OraPharma, a division of Bausch Health US, LLC, and has practiced general dentistry in suburban Philadelphia for more than 30 years. He can be reached at [email protected].
